Exercise-induced modulation of miRNAs and gut microbiome: a holistic approach to neuroprotection in Alzheimer’s disease DOI
Rui Wang, Juan Li, Xiaochen Li

et al.

Reviews in the Neurosciences, Journal Year: 2025, Volume and Issue: unknown

Published: May 7, 2025

Abstract Alzheimer’s disease (AD), a progressive neurodegenerative disorder, is marked by cognitive decline, neuroinflammation, and neuronal loss. MicroRNAs (miRNAs) have emerged as critical regulators of gene expression, influencing key pathways involved in neuroinflammation neurodegeneration AD. This review delves into the multifaceted role exercise modulating miRNA expression its interplay with gut microbiome, proposing comprehensive framework for neuroprotection By synthesizing current research, we elucidate how exercise-induced changes profiles can mitigate inflammatory responses, promote neurogenesis, reduce amyloid-beta tau pathologies. Additionally, explore gut–brain axis, highlighting exercise-driven alterations microbiota composition further influence thereby enhancing function reducing neuroinflammatory markers. holistic approach underscores potential targeting exercise-regulated miRNAs microbiome interactions novel, noninvasive therapeutic strategy to decelerate AD progression improve quality life patients. aims patient outcomes, offering promising avenue effectiveness management.

Language: Английский

Beyond the Hayflick limit: How microbes influence cellular aging DOI
Mohammad Abavisani,

Saba Faraji,

Negar Ebadpour

et al.

Ageing Research Reviews, Journal Year: 2025, Volume and Issue: 104, P. 102657 - 102657

Published: Jan. 7, 2025

Language: Английский

Citations

3
Using New Technologies to Analyze Gut Microbiota and Predict Cancer Risk DOI Creative Commons
Mohammad Amin Hemmati, Marzieh Monemi,

Shima Asli

et al.

Cells, Journal Year: 2024, Volume and Issue: 13(23), P. 1987 - 1987

Published: Dec. 1, 2024

The gut microbiota significantly impacts human health, influencing metabolism, immunological responses, and disease prevention. Dysbiosis, or microbial imbalance, is linked to various diseases, including cancer. It crucial preserve a healthy microbiome since pathogenic bacteria, such as

Language: Английский

Citations

13
Inulin‐Lipid Core–Shell Microcapsules Target the Gut Microbiota and Mimic the Pharmaceutical Food Effect for Improved Oral Antipsychotic Delivery DOI Creative Commons
Tahlia R. Meola, Aurelia S. Elz, Anthony Wignall

et al.

Advanced Functional Materials, Journal Year: 2024, Volume and Issue: 34(40)

Published: April 25, 2024

Abstract The oral delivery of most atypical antipsychotics is severely challenged by their low bioavailability and significant food effects that necessitate patient compliance. Lipid formulations are an attractive system for overcoming the dosing challenges antipsychotics, but negative impact on gut microbiota can interfere with pharmacodynamic response through disruption gut‐brain axis. Here, novel microbiota‐targeting microcapsules engineered to provide a multifunctional approach improving both pharmacokinetic properties antipsychotic, lurasidone. comprised lipid core facilitates solubilization absorption lipophilic drug outer carbohydrate polymer (inulin) shell positively modulates facilitating microbial fermentation. Fed‐fasted variability in lurasidone mitigated microencapsulation inulin‐lipid (ILM), while enrichment coupled enhanced serotonin levels small intestine, faeces, plasma. realization ILM confirms pharmacokinetics efficacy mental health therapies, such as be optimized strategic encapsulation within functional target effective modulation

Language: Английский

Citations

10
Pharmacological landscape of endoplasmic reticulum stress: uncovering therapeutic avenues for metabolic diseases DOI
Ghallab Alotaibi,

Abdullah Alkhammash

European Journal of Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 177509 - 177509

Published: March 1, 2025

Language: Английский

Citations

1
Targeting the gut microbiome to control drug pharmacomicrobiomics: the next frontier in oral drug delivery DOI
Srinivas Kamath, Andrea M. Stringer, Clive A. Prestidge

et al.

Expert Opinion on Drug Delivery, Journal Year: 2023, Volume and Issue: 20(10), P. 1315 - 1331

Published: July 5, 2023

Introduction The trillions of microorganisms that comprise the gut microbiome form dynamic bidirectional interactions with orally administered drugs and host health. These relationships can alter all aspects drug pharmacokinetics pharmacodynamics (PK/PD); thus, there is a desire to control these maximize therapeutic efficacy. Attempts modulate drug-gut have spurred advancements within field 'pharmacomicrobiomics' are poised become next frontier oral delivery.Areas covered This review details exist between microbiome, clinically relevant case examples outlining clear motive for controlling pharmacomicrobiomic interactions. Specific focus attributed novel advanced strategies demonstrated success in mediating interactions.Expert opinion Co-administration gut-active supplements (e.g. pro- pre-biotics), innovative delivery vehicles, strategic polypharmacy serve as most promising viable approaches Targeting through presents new opportunities improving efficacy by precisely PK/PD, while mitigating metabolic disturbances caused drug-induced dysbiosis. However, successfully translating preclinical potential into clinical outcomes relies on overcoming key challenges related interindividual variability composition study design parameters.

Language: Английский

Citations

21
Antipsychotic drug-induced behavioral abnormalities in common carp: The potential involvement of the gut microbiota-brain axis DOI

Xulu Chang,

Yihao Shen,

Mingqi Yang

et al.

Journal of Hazardous Materials, Journal Year: 2024, Volume and Issue: 472, P. 134444 - 134444

Published: April 30, 2024

Language: Английский

Citations

7
Emerging Role of Gut Microbiota in Breast Cancer Development and Its Implications in Treatment DOI Creative Commons
Rashid Mir,

Shrooq A. Albarqi,

Wed Albalawi

et al.

Metabolites, Journal Year: 2024, Volume and Issue: 14(12), P. 683 - 683

Published: Dec. 5, 2024

Background: The human digestive system contains approximately 100 trillion bacteria. gut microbiota is an emerging field of research that associated with specific biological processes in many diseases, including cardiovascular disease, obesity, diabetes, brain rheumatoid arthritis, and cancer. Emerging evidence indicates the affects response to anticancer therapies by modulating host immune system. Recent studies have explained a high correlation between breast cancer: dysbiosis cancer may regulate systemic inflammatory response, hormone metabolism, tumor microenvironment. Some bacteria are related estrogen which increase or decrease risk changing number hormones. Further, has been seen modulate respect its ability protect against treat cancers, focus on receptor-positive Probiotics other claiming control microbiome bacterial means might be useful prevention, even treatment, Conclusions: present review underlines various aspects clinical application, warranting individualized microbiome-modulated therapeutic approaches treatment.

Language: Английский

Citations

6
Microbiota and Cytokine Modulation: Innovations in Enhancing Anticancer Immunity and Personalized Cancer Therapies DOI Creative Commons

Hamidreza Farhadi Rad,

Hamed Tahmasebi,

Samaneh Javani

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2776 - 2776

Published: Dec. 6, 2024

The gut microbiota plays a crucial role in modulating anticancer immunity, significantly impacting the effectiveness of various cancer therapies, including immunotherapy, chemotherapy, and radiotherapy. Its impact on development is complex; certain bacteria, like

Language: Английский

Citations

4
The regulatory effects of second-generation antipsychotics on lipid metabolism: Potential mechanisms mediated by the gut microbiota and therapeutic implications DOI Creative Commons
Hui Chen, Ting Cao, Bikui Zhang

et al.

Frontiers in Pharmacology, Journal Year: 2023, Volume and Issue: 14

Published: Jan. 25, 2023

Second-generation antipsychotics (SGAs) are the mainstay of treatment for schizophrenia and other neuropsychiatric diseases but cause a high risk disruption to lipid metabolism, which is an intractable therapeutic challenge worldwide. Although exact mechanisms underlying this disturbance complex, increasing body evidence has suggested involvement gut microbiota in SGA-induced dysregulation since SGA may alter abundance composition intestinal microflora. The subsequent effects involve generation different categories signaling molecules by microbes such as endogenous cannabinoids, cholesterol, short-chain fatty acids (SCFAs), bile (BAs), hormones that regulate metabolism. On one hand, these can directly activate vagus nerve or be transported into brain influence appetite via gut–brain axis. also related metabolism peripheral pathways. Interestingly, strategies targeting metabolites seem have promising efficacy disturbances. Thus, review provides comprehensive understanding how SGAs induce disturbances altering microbiota.

Language: Английский

Citations

10
Longitudinal Gut Microbiota Dysbiosis Underlies Olanzapine-Induced Weight Gain DOI Creative Commons
豊田 隆謙, Xiaoyan He, Y. Liu

et al.

Microbiology Spectrum, Journal Year: 2023, Volume and Issue: 11(4)

Published: June 1, 2023

Olanzapine is one of the most effective second-generation antipsychotics for stabilizing schizophrenia spectrum disorders. However, olanzapine has multiple drug-induced metabolic side effects, including weight gain.

Language: Английский

Citations

10